HomeNDC LookupRxCUI directory › RxCUI 1855052

40 ML bezlotoxumab 25 MG/ML Injection — RxCUI 1855052

RxNorm drug concept · Semantic clinical drug
RxCUI 1855052 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1855052
Official name40 ML bezlotoxumab 25 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbezlotoxumab 1000 MG per 40 ML Injection; bezlotoxumab 1000 MG in 40 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bezlotoxumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, Zinplava is not an antibiotic and it doesn't kill C. diff bacteria at all. It's actually a specially engineered antibody — a protein — that targets one of the toxins C. diff pr...
  • What exactly is Zinplava doing — is it an antibiotic that kills the C. diff bacteria?
  • Great question. C. diff has a frustrating tendency to come back, especially in people considered high risk. The antibiotic you're taking tackles the active infection, but Zinplava...
  • I'm already taking an antibiotic for C. diff. Why do I need Zinplava on top of that?
📖 Read our full Bezlotoxumab Injection guide →

🕸️ Concept Web — How 40 ML bezlotoxumab 25 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 40 ML bezlotoxumab 25 MG/ML Injection RxCUI 1855052

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bezlotoxumab 1855048
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zinplava 1855053
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bezlotoxumab Injection 1855051
    • Bezlotoxumab Injectable Product 1855050
    • Bezlotoxumab Injection [Zinplava] 1855055
    • Zinplava Injectable Product 1855056
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Bezlotoxumab 25 MG/ML SCDC · 1855049
  • Bezlotoxumab Injection SCDF · 1855051
  • Bezlotoxumab Injectable Product SCDG · 1855050

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1855052 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00006-3025-00 1 VIAL, SINGLE-DOSE in 1 CARTON (0006-3025-00) / 40 mL in 1... ZINPLAVA Merck Sharp & Dohme LLC 2016-10-21
Observed labelers: Merck Sharp & Dohme LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.